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Abstract
The protective antioxidant activity of acetylcysteine (NAC) against toxicity due to 
cisplatin has been reported in experimental models; however, its efficacy in patients 
has not been elucidated. The aim of this study was to investigate the possible protec-
tive effect of NAC on cisplatin‐induced toxicity and the effect of NAC on clinical 
response and oxidative stress in patients treated for head and neck cancer. This was 
a randomized, double‐blind, placebo‐controlled trial conducted in patients receiving 
high‐dose cisplatin chemotherapy concomitant to radiotherapy. Patients were ran-
domly assigned to groups and received: (a) 600 mg NAC syrup, orally once daily at 
night for 7 consecutive days or (b) placebo, administered similarly to NAC. Nephro‐, 
oto‐, hepato‐, myelo‐, and gastrointestinal toxicities, clinical responses, and plasma 
and cellular markers of oxidative stress were evaluated. Fifty‐seven patients were 
included (n = 28, NAC arm; and n = 29, placebo arm). A high prevalence of most 
types of toxicities was observed after cisplatin chemotherapy; however, the parame-
ters were similar between the two groups. There was a predominance of partial re-
sponse to treatment. In the cellular and plasmatic oxidative stress analyses, minor 
differences were observed. Overall, there was no statistically significant difference 
between the groups for all outcomes. These findings show that low‐dose oral NAC 
does not protect patients with head and neck cancer from cisplatin‐induced toxicities 
and oxidative stress. The antitumor efficacy of cisplatin was apparently not impaired 
by NAC.
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1 |  INTRODUCTION
Cisplatin is an anticancer drug most effective for the treat-
ment of solid tumors, such as head and neck cancer. However, 
cisplatin causes nephrotoxicity, ototoxicity, hepatotoxicity, 
myelosuppression, and nausea and vomiting, which limit its 
use. Our previous studies showed that patients experienced 
anemia, lymphopenia, and nausea; had significant changes in 
serum creatinine and creatinine clearance; and experienced 
a reduction in the quality of life following treatment with 
cisplatin.1,2
Oxidative stress is the main mechanism responsible for 
cisplatin‐induced toxicity. It is known that cisplatin leads 
to the generation of mitochondrial reactive oxygen species 
(ROS).3,4 In addition, cisplatin binds to glutathione by glu-
tathione‐S‐transferase to be eliminated from the cell, thus 
depleting cellular glutathione content.5 Consequently, after 
cisplatin treatment, oxidative stress biomarkers increase in 
the plasma and urine and antioxidants decrease.6-10 Based 
on this, several antioxidant compounds have been studied 
as possible protective agents against toxicities caused by 
cisplatin.6,7
Acetylcysteine (NAC) is a drug used in clinical practices 
as a mucolytic agent, as an antidote for paracetamol poison-
ing, and as a protector of contrast‐induced nephropathy. It 
possesses antioxidant properties and is also a glutathione 
precursor.14 NAC has been studied in the context of cispla-
tin‐induced toxicities, and has been shown to protect against 
nephrotoxicity,14 ototoxicity,15 and hepatotoxicity16 in animal 
models and in vitro; however, its efficacy in patients has not 
been elucidated.
In terms of the effect of antioxidants on the clinical re-
sponses to cisplatin, the findings of one study suggested that 
antioxidants may decrease cisplatin's antitumor efficacy.17 
Contrarily, an animal model study showed that the admin-
istration of NAC 4 h after cisplatin administration did not 
affect the antitumor action of cisplatin, in contrast to when 
NAC was administered 30 min earlier.18
The aim of this study was to investigate the possible pro-
tective effect of NAC on cisplatin‐induced toxicities and the 
effect of NAC on the clinical responses and oxidative stress in 
patients treated with cisplatin for head and neck cancer. This 
is the first randomized, double‐blind, placebo‐controlled trial 
to investigate this issue.
2 |  METHODS
2.1 | Study design
This was a randomized, double‐blind, placebo‐controlled trial 
conducted from March 2015 to February 2017 at the clini-
cal oncology department of a teaching hospital in São Paulo, 
Brazil. The Research Ethics Committee of the institution 
approved this study (number 30216814.9.0000.5404), and 
all patients signed a consent form authorizing the use of 
their data. The study was registered in ClinicalTrials.gov 
(NAC + Cisplatin2014, NCT 02241876).
2.2 | Eligibility criteria
The study included outpatients with head and neck squamous 
cell carcinomas (oral cavity, oropharynx, hypopharynx, and 
larynx), who had not undergone any previous oncologi-
cal treatment (surgery, chemotherapy, or radiotherapy) and 
were on high‐dose cisplatin chemotherapy with concurrent 
radiotherapy.
Patients were excluded if: distant metastasis or a second 
primary tumor was present; they declined to participate at 
any time during the course of the study; died before the start 
of the treatment; changed their chemotherapy protocol before 
the start of the treatment (cisplatin had been prescribed; how-
ever, for some reason, cisplatin was contraindicated and the 
prescription changed); did not tolerate the use of syrup or 
were administered the syrup <70% of the time; or were re-
ceiving nephrotoxic and ototoxic drugs during the treatment.
2.3 | Cancer treatment protocol
Chemotherapy comprised three cycles of high‐dose 
(80‐100 mg/m2) cisplatin administered on days 1, 22, and 43. 
On each day of chemotherapy, the patients received vigorous 
hydration (3 L of saline solution 0.9%), diuretics (125 mL of 
mannitol 20%), electrolytes (20 mL of potassium chloride 
19.1% and 10 mL of magnesium sulfate 10%), and prophy-
laxis of acute emesis (20 mg of dexamethasone plus 24 mg 
of ondansetron).
Concomitant with the three cycles of chemotherapy, the 
patients received 70 Gy of radiation therapy divided into 
35 daily applications of 2 Gy administered for 5 days per 
week for 7 weeks. Radiation was performed using cobalt‐60 
(Alcyon II, GE, France) and a linear accelerator (6 MV) 
(Varian Medical Systems, CA).
2.4 | NAC and placebo arms
Patients included in the study were randomized into an NAC 
arm or a placebo arm through a randomization system (http://
www.randomizer.org/). Both the researchers and the patients 
were blinded to this process during the study.
Patients in the NAC arm received 600 mg of NAC syrup 
(EMS®) administered orally once daily at night for 7 con-
secutive days (2 days before chemotherapy, on the day of 
chemotherapy, and 4 days after chemotherapy) in each cycle 
of chemotherapy. Those in the placebo arm received syrup 
without the NAC ingredient with the same schedule as the 
NAC arm. The excipients of both syrups were: propylene 
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glycol, sodium hydroxide, sodium cyclamate, sodium saccha-
rin, methylparaben, hyetellose, disodium EDTA, raspberry 
essence, propylparaben, and purified water. A self‐reported 
compliance form was used to monitor adherence to syrup 
consumption.
2.5 | Demographic and clinical data
Data regarding patient characteristics were obtained from 
medical records and interviews with patients, including 
information concerning age, gender, race, comorbidities, 
Karnofsky Performance Status (KPS),19 smoking and drink-
ing categories based on the studies by Jindal et al20 and 
Whitcomb et al,21 tumor differentiation, and the site and 
TNM stage of tumors.22
2.6 | Toxicity of treatment
Each patient had their blood collected prior to cisplatin ad-
ministration, and 5 and 20 days after each treatment cycle. 
Thus, nephrotoxicity (increased serum creatinine, decreased 
creatinine clearance estimated using the Cockcroft—Gault 
formula, hyperuricemia, hyponatremia, hypomagnesemia, 
hypokalemia, hypophosphatemia, and hypocalcemia), hepa-
totoxicity (hypoalbuminemia, increased serum level of as-
partate aminotransferase, alanine aminotransferase, alkaline 
phosphatase, and total bilirubin), and myelotoxicity (anemia, 
leukopenia, neutropenia, lymphopenia, and thrombocytope-
nia) were investigated. Gastrointestinal toxicity (nausea and 
vomiting) was also studied considering the symptoms on day 
1 (first 24 h after chemotherapy—acute phase) through day 5 
(24‐120 h after chemotherapy—delayed phase). Furthermore, 
audiometric tests were performed before and 20 days after 
the end of cisplatin treatment to analyze ototoxicity. All tox-
icities were graded according to National Cancer Institute 
Common Toxicity Criteria for Adverse Events version 4.23
2.7 | Clinical response
Before starting treatment and 30 days after the end of the 
treatment, the patients underwent computed tomography or 
magnetic resonance imaging. Clinical responses were clas-
sified into complete response, partial response, progres-
sive disease, and stable disease according to the Response 
Evaluation Criteria in Solid Tumors 1.1 (RECIST 1.1).24
2.8 | Cellular and plasmatic oxidative stress
Blood was collected prior to cisplatin administration, and 
at 5 and 20 days after initiating therapy. The blood was col-
lected in vacuum tubes containing EDTA or citrate as the 
anticoagulant. For the cellular oxidative stress analysis, pe-
ripheral blood mononuclear cells (PBMCs) were isolated 
using HISTOPAQUE‐1077 (Sigma‐Aldrich, St. Louis, 
MO). Mitochondrial superoxide anion (O2
•‐) and cellular 
H2O2 production were measured using MitoSOX
TMRed and 
Amplex® Red reagent, respectively, according to Quintanilha 
et al25. Other oxidative stress biomarkers, including free 8‐
isoprostane, malondialdehyde (MDA), and total antioxidant 
capacity (TAC), were measured in the plasma obtained by 
centrifugation of whole blood. The levels of 8‐isoprostane 
were determined by enzyme‐linked immunosorbent assay 
(8‐Isoprostane EIA Kit; Cayman Chemical Company, 
USA). MDA and TAC were measured by colorimetric as-
says (TBARS Assay Kit and Antioxidant Assay Kit; Cayman 
Chemical Company).
2.9 | Sample calculation
Grades of increased serum creatinine (primary endpoint) 
of the first 12 patients to complete the study were used for 
sample calculation. This was performed using the Statistical 
Analysis System for Windows (SAS 9.4., SAS Institute Inc, 
2002‐2008, Cary, NC). This initial analysis showed that it 
would be necessary to include 42 patients (21 per arm).
2.10 | Data analysis
Descriptive analyses were performed on absolute frequen-
cies and percentages for categorical variables. Numerical 
variables were described by the mean and standard deviation. 
Statistical analyses were performed using the SAS 9.4 (SAS 
Institute Inc). Mann‐Whitney test was used to compare nu-
merical variables, and Chi‐square or Fisher's exact tests were 
used to compare categorical variables between arms. The sig-
nificance level for all analyses was 5% (P < 0.05).
3 |  RESULTS
3.1 | Studied patients and characteristics
Ninety‐seven patients provided informed consent; however, 
only 57 patients were analyzed (28 patients in the NAC arm 
vs 29 patients in the placebo arm) (Figure 1). In general, 
baseline characteristics did not differ between the 2 arms 
(Table 1). Not all patients were able to complete the 3 treat-
ment cycles (Figure 2).
3.2 | Toxicities of treatment
Table 2 shows the toxicities of treatment and grades of se-
verity, considering the highest grade obtained during treat-
ment. Decreased creatinine clearance, hypomagnesemia, 
anemia, lymphopenia, nausea, and hearing impairment 
were the most frequent toxicities in both arms. When the 
arms were compared in relation to the grades of toxicity, 
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there were no statistical differences, except for neutrope-
nia where the NAC arm presented more severe neutropenia 
(grades 3 and 4). There was also no significant difference 
between arms when the grades of toxicity of serum creati-
nine (primary endpoint) were assessed per treatment cycle 
(Table 3).
3.3 | Clinical response
Clinical responses were evaluated in 25 patients of the pla-
cebo arm and in 24 patients of the NAC arm (4 patients in 
the NAC arm died before the exam; 3 patients in the pla-
cebo arm died; and in 1 case it was not possible to classify 
the clinical response). The 7 cases of acute death occurred 
due to cancer complications. The majority of patients had 
partial responses (72.0% in the placebo arm and 62.5% in 
the NAC arm), followed by complete response (24.0% in 
the placebo arm and 25.0% in the NAC arm) and progres-
sive disease (4.0% in the placebo arm and 12.5% in the NAC 
arm). No patient was classified as having stable disease. 
Comparison of the clinical responses between the arms 
showed no statistical difference (P value = 0.9351, Chi‐
square test, complete response vs partial response + pro-
gressive disease).
3.4 | Cellular and plasmatic oxidative stress
For these analyses, only the baseline data and data obtained 
after the first cycle (post 5 and 20 days) are presented (Table 
4). The placebo and NAC arms did not show any significant 
difference in the values of cellular and plasma oxidative 
stress biomarkers at any time point (including in the other 
treatment cycles; the data are not presented here because the 
number of samples was reduced).
F I G U R E  1  Flow diagram of the passage of participants through the trial. NAC = acetylcysteine, n = number of participants
Assessed for eligibility (n = 97)
Excluded (n = 33)
− Switched chemotherapy protocol (n = 21)
− Declined to participate (n = 4)
− Death (n = 4)
− Other reasons (n = 4)
Analysed (n = 29)
− Patient used nephrotoxic drug and was excluded from 
the analysis (n = 1)
Follow-up completed (n = 30)
− Lost to follow-up (n = 0)
Allocated to Placebo arm (n = 30)
Follow-up completed (n = 28)
− Noncompliance to intervention (<5 d of use) (n = 5) 
− Lost to follow-up (n = 1)
Allocated to NAC arm (n=34)




Randomised (n = 64)
Enrollment
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n = 28 P value
Age mean ± SD, years 56.6 ± 7.8 55.9 ± 8.8 0.8354(a)
BMI mean ± SD, kg/m2 22.6 ± 4.9 22.0 ± 3.2 0.8729(a)
Gender, n (%)   0.6701(b)
Men 27 (93.1) 25 (89.3)  
Women 2 (6.9) 3 (10.7)  
Race, n (%)   0.7297(b)
White 23 (79.3) 24 (85.7)  
Non‐white 6 (20.7) 4 (14.3)  
Smoking category, n (%)   0.1646(c)
Non‐smokers 1 (3.4) 4 (14.3)  
Light smokers 1 (3.4) 3 (10.7)  
Moderate smokers 3 (10.4) 2 (7.1)  
Heavy smokers 24 (82.8) 19 (67.9)  
Drinking category, n (%)   0.2798 (c)
Abstainers 2 (6.9) 3 (10.7)  
Light drinkers 0 (0.0) 0 (0.0)  
Moderate drinkers 7 (24.1) 2 (7.1)  
Heavy drinkers 7 (24.1) 6 (21.4)  
Very heavy drinkers 13 (44.9) 17 (60.8)  
KPS, n (%)   0.5575 (b)
100 2 (6.9) 4 (14.3)  
90 21 (72.4) 17 (60.7)  
80 6 (20.7) 7 (25.0)  
Tumor site, n (%)   0.9034 (c)
Oropharynx 15 (51.8) 15 (53.6)  
Larynx 8 (27.6) 9 (32.2)  
Oral cavity 4 (13.8) 2 (7.1)  
Hypopharynx 1 (3.4) 2 (7.1)  
Oropharynx +oral cavity (synchronic 
tumors)
1 (3.4) 0 (0.0)  
Tumor differentiation, n (%)   0.7348 (b)
Well differentiated 1 (3.5) 3 (10.7)  
Moderately differentiated 17 (58.6) 19 (67.9)  
Poorly differentiated 3 (10.3) 3 (10.7)  
Undifferentiated 0 (0.0) 0 (0.0)  
Not evaluated 8 (27.6) 3 (10.7)  
T stage, n (%)   0.9164 (c)
T1 1 (3.5) 1 (3.6)  
T2 5 (17.2) 2 (7.1)  
T3 5 (17.2) 6 (21.4)  
T4 18 (62.1) 17 (60.8)  
Tx 0 (0.0) 2 (7.1)  
N stage, n (%)   0.3514 (c)
(Continues)
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4 |  DISCUSSION
In this study, we investigated whether NAC could attenuate 
the cisplatin‐induced toxicities and oxidative stress in patients 
with head and neck cancer without impairing the response to 
treatment. Although preclinical data suggested a protective 
effect of NAC and other antioxidants, in our study, NAC did 
not limit toxicities and oxidative stress due to cisplatin.
Nephrotoxicity has been the most studied adverse ef-
fect of cisplatin and is also commonly studied to test the 
ability of antioxidants to attenuate cisplatin‐induced tox-
icities. In particular, NAC can inhibit oxidative stress, 
and consequently, the cisplatin‐activated signaling cas-
cade (MAPK p58, caspase‐3, and NF‐κB) that leads to 
renal cell apoptosis.26 As observed by Shalby et al,27 
NAC can also attenuate nephrotoxicity through its anti‐in-
flammatory properties, since it reduces the production of 
pro‐inflammatory cytokines26,28,29 and inhibits the activ-
ity of neutrophils and NF‐κB that mediate the cascade of 
inflammation.30
Abdel‐Wahab et al14 observed beneficial effects of NAC 
and taurine against cisplatin‐induced nephrotoxicity. Rats re-
ceived NAC and/or taurine intraperitoneally after 3 days of 
cisplatin administration 3 times per week for 4 consecutive 
weeks. Cisplatin caused nephrotoxicity and oxidative stress, 
and NAC (with or without taurine) significantly improved 
the renal function of cisplatin‐treated rats and attenuated ox-
idative stress in renal tissue (MDA and TAC tests). Similar 
results were also obtained by Shalby et al.27
Unlike reports in the literature, we did not observe the 
protective effect of NAC against nephrotoxicity. In previ-
ous studies, high doses of NAC were used intraperitone-
ally in animal models. In our study, considering an average 





n = 28 P value
N0 6 (20.7) 4 (14.3)  
N1 2 (6.9) 5 (17.8)  
N2 17 (58.6) 18 (64.3)  
N3 4 (13.8) 1 (3.6)  
Stage, n (%)   0.1086 (c)
I 0 (0.0) 1 (3.6)  
II 1 (3.4) 0 (0.0)  
III 0 (0.0) 3 (10.7)  
IV 28 (96.6) 24 (85.7)  
Comorbidities, n (%)   0.5027 (c)
Systemic arterial hypertension 11 (37.9) 4 (14.3)  
Diabetes mellitus 3 (10.3) 4 (14.3)  
Arrhythmia and other cardiovascular 
diseases, except SAH
2 (6.9) 0 (0.0)  
Depression 2 (6.9) 0 (0.0)  
Gastroesophageal reflux disease 1 (3.4) 1 (3.6)  
Hypothyroidism 1 (3.4) 1 (3.6)  
Arthrosis 1 (3.4) 1 (3.6)  
Other 4 (13.8) 4 (14.3)  
Note. BMI: Body Mass Index, KPS: Karnofsky Performance Status, n: absolute number, SAH: Systemic arterial hypertension, SD: standard deviation. (a)Mann‐Whitney 
test, (b)Fisher's exact test, (c)Chi‐square test.
Groups were formed to perform the statistical tests for the following categories: smoking = heavy smokers vs moderate + light + non‐smokers; drinking = very 
heavy + heavy drinkers vs moderate + light drinkers + abstainers; tumor site = oropharynx vs other sites; tumor differentiation = moderately differentiated vs 
well + poorly differentiated + undifferentiated; T stage = T4 vs T1 + T2 + T3; N stage = N0 + N1 vs N2 + N3; stage = IV vs I + II + III; comorbidities = have comor-
bidities vs have no comorbidities.
Smoking category was classified based on the study by Jindal et al20. Patients were classified as non‐smokers if they reported never having smoked; light, moderate, and 
heavy smokers were smokers and ex‐smokers, and they were classified according to the smoking index (SI), which was the product of the average number of cigarettes 
smoked per day and the duration of smoking in years; light (SI = 1‐100), moderate (SI = 101‐300), and heavy (SI ≥ 301) smokers.
Drinking category was classified based on the study by Whitcomb et al21. Average weekly alcohol intake during the maximum lifetime drinking period (drinks/wk): 
abstainers, no alcohol use or <20 drinks in lifetime; light drinkers, ≤3 drinks/wk; moderate drinkers, 4‐7 drinks/wk for females and 4‐14 drinks/wk for males; heavy 
drinkers, 8‐34 drinks/wk for females and 15‐34 drinks/week for males; very heavy drinkers, ≥35 drinks/week.
Other comorbidities: asthma, bronchitis, chronic obstructive pulmonary disease, fibromyalgia, hepatic cirrhosis, hepatitis B, hypercholesterolemia, labyrinthitis.
T A B L E  1  (Continued)
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F I G U R E  2  Placebo and NAC arms: number of participants, cisplatin cycles and doses. Considering the placebo arm, from 29 patients that 
underwent the first cycle, only 19 underwent the second cycle (19/29; 65.5%), and 14 underwent the third cycle (14/29; 48.3%). In the NAC arm, 23 
from 28 patients underwent the second cycle (23/28; 82.1%) and 16 underwent the third cycle (16/28; 57.1%). In addition, 10 patients in the placebo 
arm (10/29; 34.5%) had their dose of cisplatin reduced after the first cycle, vs 6 in the NAC arm (6/28; 21.4%). After the second cycle, 4 patients 
in the placebo arm had a dose reduction (4/19; 21.1%) vs 4 in the NAC arm (4/23; 17.4%). The reasons for dose reduction or fewer cycles were 
toxicities and death. The NAC arm underwent more cisplatin cycles and had less dose reduction during treatment
T A B L E  2  Grades of toxicity and comparison between arms
Toxicities/Grades
Placebo arm (%) 
n = 29
NAC arm (%) 
n = 28
P values0 1 2 3 4 0 1 2 3 4
Increased serum 
creatinine
44.8 20.7 13.8 20.7 0.0 35.7 25.0 21.4 17.9 0.0 0.6517 (†) (a)
Decreased creatinine 
clearance*
3.5 31.0 44.8 17.2 3.5 3.6 28.6 53.5 10.7 3.6 0.8620 (‡) (a)
Hyperuricemia 72.4 27.6 0.0 0.0 0.0 75.0 14.3 0.0 0.0 10.7 0.8246 (†) (b)
Hyponatremia 31.0 51.7 — 10.4 6.9 32.1 28.6 — 28.6 10.7 0.1128 (†) (a)
Hypomagnesemia 13.8 75.9 10.3 0.0 0.0 10.7 67.9 14.3 7.1 0.0 1.0000 (‡) (b)
Hypokalemia 96.6 3.4 0.0 0.0 0.0 89.3 10.7 0.0 0.0 0.0 0.3525 (‡) (b)
Hypophosphatemia 75.9 — 24.1 0.0 0.0 89.3 — 10.7 0.0 0.0 0.2973 (‡) (b)
Hypocalcemia 48.3 41.4 10.3 0.0 0.0 60.7 32.1 7.1 0.0 0.0 0.3459 (†) (b)
Hearing impaired 24.0 32.0 28.0 16.0 0.0 20.8 16.7 25.0 37.5 0.0 0.3333 (†) (c)
Hypoalbuminemia 62.1 17.2 20.7 0.0 0.0 64.3 17.8 14.3 3.6 0.0 0.8623 (†) (b)
Increased AST 96.6 3.4 0.0 0.0 0.0 89.3 10.7 0.0 0.0 0.0 0.3525 (‡) (b)
Increased ALT 69.0 31.0 0.0 0.0 0.0 75.0 21.4 3.6 0.0 0.0 0.6122 (†) (b)
Increased ALP 89.7 10.3 0.0 0.0 0.0 89.3 10.7 0.0 0.0 0.0 1.0000 (‡) (b)
Increased total 
bilirubin
93.2 3.4 0.0 0.0 0.0 96.4 3.6 0.0 0.0 0.0 1.0000 (‡) (b)
Anemia 6.9 34.5 41.4 17.2 0.0 7.1 50.0 39.3 3.6 0.0 0.2832 (‡) (a)
Leukopenia 24.1 17.3 44.8 13.8 0.0 28.6 21.4 25.0 21.4 3.6 0.4329 (†) (a)
Neutropenia 44.8 20.7 27.6 6.9 0.0 42.8 14.3 10.7 28.6 3.6 0.0332 (†) (a)
Lymphopenia 6.9 0.0 20.7 62.1 10.3 3.6 3.6 14.3 71.4 7.1 1.0000 (‡) (a)
Thrombocytopenia 65.5 34.5 0.0 0.0 0.0 53.6 46.4 0.0 0.0 0.0 0.3581 (†) (b)
Nausea 24.1 17.2 27.6 31.1 — 14.2 25.0 42.9 17.9 — 0.2155 (†) (a)
Vomiting 41.4 24.1 13.8 20.7 0.0 50.0 14.2 17.9 17.9 0.0 0.8076 (†) (a)
Note. (†) Chi‐square test. (‡) Fisher's exact test. (a) Grade 0 vs grades 1 + 2 vs grades 3 + 4. (b) Grade 0 vs grades 1 + 2 + 3 + 4. (c) Grade 0 vs grade 1 vs grade 2 vs grade 
3. — there is no grade for this toxicity. n: absolute number of patients. NAC: acetylcysteine, AST: aspartate aminotransferase. ALT: alanine aminotransferase. ALP: 
alkaline phosphatase. * Cockcroft–Gault formula.
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for 7 days, approximately 10 mg/kg/d of NAC was ad-
ministered to the patients, totaling 70 mg/kg. Studies that 
showed an important effect of NAC on nephrotoxicity used 
doses of 50 mg/kg/d (total 600 mg/kg),14 50 mg/kg/d (total 
of 1200 mg/kg),27 500 mg/kg/d (total of 2000 mg/kg),31 
and 500 mg/kg/d (total of 4500 mg/kg)32; therefore, our 
dose corresponds to 2%‐20% of the daily dose and 2%‐12% 
of the total doses reported in these studies. Moreover, the 
oral bioavailability of the intact NAC  molecule is low, from 
4% to 10%, owing to its binding to plasm a  proteins and 
the deacetylation that it undergoes in the intestinal mucosa 
and lumen.33-36 One study showed that the levels of protec-
tion against cisplatin‐induced nephrotoxicity depend on the 
route of administration of NAC, and only the intravenous 
route was effective.37
Previous studies have also shown that NAC was effective 
in attenuating cisplatin‐induced ototoxicity15,38 and hepato-
toxicity,16 in contrast to the current study, probably owing to 
the different doses, schedules, and routes chosen. No study 
using NAC against myelotoxicity, nausea, and vomiting in-
duced by cisplatin was found; however, research using other 
antioxidants showed beneficial results.7,39-42 In this study, 
we also quantified ROS in PBMCs, lipid peroxidation, and 
TAC in the plasma as markers of oxidative stress. Our results 
showed that the NAC and placebo arms did not differ in these 
analyses.
It is known that antioxidants can increase cell prolifera-
tion in tumors43 or impair the effect of antineoplastic drugs.17 
However, studies have shown no evidence that antioxidants 
were associated with decreased survival or tumor responses.44 
In the case of NAC, as it is a precursor of glutathione which 
participates in the mechanism of cisplatin inactivation, the 
effect of cisplatin could be reduced. In addition, NAC may 
inhibit the pathway by which cisplatin induces apoptosis 
(caspases), impairing its cytotoxic action.45 Muldoon et al,18 
using a tumor model, showed that when NAC  is administered 
30 min before cisplatin administration, a reduction in the ac-
tion of cisplatin may occur, but not when it is administered 
4 h after. According to Dickey et al,37 the reduction in the 
antineoplastic effect of cisplatin could be avoided by sepa-
rating cisplatin and NAC administration spa t iotemporally. 
Robbins et al46 determined that this space separation occurs 
owing to the administration of cisplatin and  NAC through 
different routes. In our study, NAC administration and cispla-
tin administration were spatiotemporally separated, and there 
was no difference in clinical response between the patients 
receiving NAC and placebo.
The antioxidant type, dose, route, and regimen of ad-
ministration used in our study were based on a few fac-
tors. Among the several compounds that have been studied 
in an attempt to prevent the toxicities of cisplatin, such as 
some vitamins and minerals, taurine, dimethylurea, d‐me-
thionine, and linseed oil, NAC   was chosen for this study 
since animal model studies showe d  promising results of 
NAC  in the attenuation of cisplatin toxicities. NAC is also 
a drug approved in Brazil and easy to access (low cost), 
Cycle/grades Placebo arm (%) NAC arm (%) P value


















Note. (†) Chi‐square test. (‡) Fisher's exact test. (a) Grade 0 vs grades 1 + 2 vs grades 3 + 4. (b) Grade 0 vs grades 
1 + 2 + 3 + 4. n: absolute number of patients, NAC: acetylcysteine.
T A B L E  3  Grades of toxicity of 
increased serum creatinine after each 
cisplatin cycle and comparison between 
arms
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safe, and does not present frequent adverse effects, and 
therefore, was considered to be a good candidate to be 
included as a support medication during treatment with 
cisplatin. The choice of dosage form (syrup) and route of 
administration (oral) were made, because oral use is non-
invasive and the placebo was easier to prepare. Intravenous 
administration of NAC   for 7 days would have been diffi-
cult because the patients studied were not hospitalized. In 
relation to the dose, we opted to supplement patients at a 
low‐dose to not interfere with antitumor efficacy, since the 
doses used in animal models were extremely high, and the 
effect on tumor progress ion has not yet been fully eluci-
dated in the literature.  The chosen dose has already been 
used in another study3 8 and is approved by the Brazilian 
Health Regulatory Agenc y  (Anvisa) for the treatment of 
productive cough. The syrup was given once a day at night 
to facilitate patient adherence. Thus, there was an interval 
between the administration of cisplatin and NAC (~12 h). 
NAC was administered 2 d ays before chemotherapy as a 
prophylaxis and on the subsequent 5 days, when the main 
toxicities, such as nau s ea, vomiting, nephrotoxicity, and 
oxidative stress, were likely to occur.
The limitations of our  study included difficulties with 
blood sample collection  for oxidative stress assays; at one 
time, some patients were so debilitated that the health pro-
fessional had difficulty accessing their veins. We performed 
analysis during all 3 cycles of chemotherapy; however, the 
oxidative stress analyses were impaired after the second cycle 
of treatment owing to loss of samples due to these reasons. 
Regarding cellular oxidative stress assays, the large variances 
when performing statistical analyses may be a consequence 
of the complexity of the assays, in which readings can be in-
fluenced by many factors, such as minor differences in pH, 
temperature, and air bu b bles in the reaction chamber and 
plate. It is our pleasure to recommend a few suggestions for 
further trials in this a rea: include a greater number of par-
ticipants; test other doses, schedules, and routes of adminis-
tration of NAC; perform the second radiological assessment 
8 or 12 weeks after completion of treatment to decrease the 
false‐positives related  to local inflammation and fibrosis 
induced by chemoradiation; and determine late deaths and 
overall survival in both arms.
Although this study has shown that the use of NAC was 
not effective in attenuating the toxicity of cisplatin in patients 
 
Placebo arm (n = 29) NAC arm (n = 28)
P valuen Mean ± SD n Mean ± SD
O2
•‐, MFI      
Baseline 27 398.0 ± 508.4 27 293.8 ± 263.9 0.7952
5 days 23 286.8 ± 283.5 26 287.4 ± 250.1 0.3214
20 days 23 240.4 ± 237.7 21 286.9 ± 411.4 0.7960
H2O2, nmol H2O2/s 
(×10‐14)
     
Baseline 28 2.8 ± 2.2 28 2.1 ± 2.0 0.2041
5 days 26 2.8 ± 2.3 27 2.3 ± 1.5 0.6889
20 days 25 3.2 ± 6.6 24 2.3 ± 1.7 0.1971
MDA, µM      
Baseline 26 9.1 ± 5.4 28 11.7 ± 6.6 0.1191
5 days 26 14.9 ± 8.1 28 13.9 ± 5.8 0.2989
20 days 24 12.6 ± 5.6 25 13.2 ± 7.3 0.2420
8‐Isoprostane, pg/mL      
Baseline 24 41.9 ± 34.1 26 62.2 ± 52.5 0.0875
5 days 24 49.8 ± 28.6 26 62.0 ± 48.2 0.1772
20 days 20 63.3 ± 93.9 21 39.0 ± 41.1 0.1087
TAC, mM      
Baseline 22 1.4 ± 0.4 26 1.4 ± 0.5 0.9670
5 days 22 1.5 ± 0.5 26 1.6 ± 0.6 0.7250
20 days 22 1.3 ± 0.4 23 1.4 ± 0.5 0.2708
Note. Mann‐Whitney test. The comparison between the arms for 5 and 20 days was based on variation from 
baseline.
MDA: malondialdehyde, MFI: mean fluorescence intensity, n: absolute number of patients evaluated, NAC: 
acetylcysteine, SD: standard deviation, TAC: total antioxidant capacity.
T A B L E  4  Cellular and plasmatic 
oxidative stress biomarkers and comparison 
between arms
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with head and neck cancer, this was the first double‐blind, 
placebo‐controlled, randomized trial using this approach, 
and should form a basis to conduct new studies in humans. 
It is a challenge for future clinical studies to identify an op-
timal dose and regimen for NAC delivery to protect against 
cisplatin toxicities without compromising its antineoplastic 
efficacy during clinical treatment.
5 |  CONCLUSION
Low‐dose oral NAC does not protect patients with head and 
neck cancer from cisplatin‐induced toxicities and oxidative 
stress. The antitumor efficacy of cisplatin was apparently not 
impaired by NAC. Further clinical studies should be con-
ducted to test other doses, schedules, and routes of adminis-
tration of NAC.
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